Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NKTX Nkarta Inc
- Stocks
- Healthcare
- NASDAQ: NKTX
Price (delayed)
$1.89
Market cap
$134.11M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.5
Enterprise value
$157.68M
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off the shelf natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with
Highlights
NKTX's EPS is up by 36% year-on-year and by 6% since the previous quarter
NKTX's debt is down by 9% year-on-year
Nkarta's net income has increased by 4.3% YoY but it has decreased by 2.3% QoQ
NKTX's quick ratio is down by 28% year-on-year
Nkarta's equity has decreased by 20% YoY and by 7% QoQ
Key stats
What are the main financial stats of NKTX
Market
Valuations
Earnings
Shares outstanding
70.96M
Market cap
$134.11M
Enterprise value
$157.68M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.35
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$132M
Net income
-$111.26M
EBIT
-$111.26M
EBITDA
-$99.88M
Free cash flow
-$105.55M
Per share
Balance sheet
Liquidity
EPS
-$1.5
EPS diluted
-$1.5
Free cash flow per share
-$1.43
Book value per share
$5.34
Revenue per share
$0
TBVPS
$6.37
Total assets
$470.61M
Total liabilities
$91.8M
Debt
$78.91M
Equity
$378.81M
Working capital
$252.8M
Debt to equity
0.21
Current ratio
14.48
Quick ratio
14.3
Net debt/EBITDA
-0.24
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-21.6%
Return on equity
-26.6%
Return on invested capital
-21.8%
Return on capital employed
-24.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NKTX stock price
How has the Nkarta stock price performed over time
Intraday
6.78%
1 week
7.39%
1 month
-9.57%
1 year
-71.32%
YTD
-24.1%
QTD
2.72%
Financial performance
How have Nkarta's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$132M
Net income
-$111.26M
Gross margin
N/A
Net margin
N/A
Nkarta's net income has increased by 4.3% YoY but it has decreased by 2.3% QoQ
Nkarta's operating income has decreased by 3% from the previous quarter
Price vs fundamentals
How does NKTX's price correlate with its fundamentals
Growth
What is Nkarta's growth rate over time
Valuation
What is Nkarta stock price valuation
P/E
N/A
P/B
0.35
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NKTX's EPS is up by 36% year-on-year and by 6% since the previous quarter
The P/B is 79% below the 5-year quarterly average of 1.7 and 42% below the last 4 quarters average of 0.6
Nkarta's equity has decreased by 20% YoY and by 7% QoQ
Efficiency
How efficient is Nkarta business performance
NKTX's return on equity is up by 22% year-on-year but it is down by 8% since the previous quarter
NKTX's return on invested capital is up by 21% year-on-year and by 2.2% since the previous quarter
The ROA has grown by 17% YoY but it has contracted by 7% from the previous quarter
Dividends
What is NKTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NKTX.
Financial health
How did Nkarta financials performed over time
NKTX's quick ratio is down by 28% year-on-year
The current ratio has contracted by 27% YoY
NKTX's debt is 79% smaller than its equity
Nkarta's equity has decreased by 20% YoY and by 7% QoQ
NKTX's debt to equity is up by 17% year-on-year and by 5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.